Roche’s Virtual Pipeline Event from WFH 2018 World CongressRegistration available from (CET timezone): 17.00, 23 May 2018
Karl Mahler, Head of Investor Relations
Hemophilia A without inhibitors remains an unmet medical need
Cristin Hubbard, Lifecycle Leader Hemlibra (emicizumab)
HAVEN 3: Phase 3 study of emicizumab prophylaxis in persons with hemophilia A without inhibitors
Johnny Mahlangu, MBBCh, MMed, Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa
HAVEN 4: Phase 3 study of emicizumab prophylaxis given every 4 weeks in persons with hemophilia A with and without inhibitors; additional comments
Gallia Levy, MD, Associate Group Medical Director Hematology
Audio Webcast Replay
Please fill out the form to access the Audio webcast replay.
The registration form for the webcast is not available.
Please come back 30 minutes before the webcast start date and fill in the registration form.